Get the Stockscreener App
13.01
4.13%
-0.56
Pre-market:
11.61
-1.40
-10.76%
Arcus Biosciences Inc Stock (RCUS) Latest News
Arcus Biosciences appoints new board member - Investing.com
Arcus Biosciences Appoints New Board Director - TipRanks
Arcus Biosciences Inc (RCUS) may enjoy gains as insiders got busy in the recent days - Knox Daily
Stocks of Arcus Biosciences Inc (RCUS) are poised to climb above their peers - SETE News
Arcus Biosciences (NYSE:RCUS) Hits New 52-Week LowWhat's Next? - MarketBeat
Arcus Biosciences' SWOT analysis: stock poised for growth amid clinical trials - MSN
Arcus Biosciences (NYSE:RCUS) Shares Up 4.1%Still a Buy? - MarketBeat
SG Americas Securities LLC Reduces Stake in Arcus Biosciences, Inc. (NYSE:RCUS) - Defense World
Arcus Biosciences (NYSE:RCUS) Hits New 12-Month LowShould You Sell? - MarketBeat
Arcus Biosciences stock hits 52-week low at $12.86 - MSN
Arcus Biosciences stock hits 52-week low at $12.86 By Investing.com - Investing.com Australia
Relative Strength Alert For Arcus Biosciences - Nasdaq
JPMorgan Chase & Co. Purchases 1,117 Shares of Arcus Biosciences, Inc. (NYSE:RCUS) - Defense World
When the Price of (RCUS) Talks, People Listen - Stock Traders Daily
Arcus Biosciences Grants Stock Options and RSUs to New Key Employees - StockTitan
Arcus Biosciences (NYSE:RCUS) Stock Quotes, Forecast and News Summary - Benzinga
Arcus Biosciences (NYSE:RCUS) Stock Price Down 4.5%Here's What Happened - MarketBeat
Arcus Biosciences (NYSE:RCUS) Reaches New 12-Month LowHere's What Happened - MarketBeat
Cantor Fitzgerald Forecasts RCUS FY2025 Earnings - Defense World
Arcus Biosciences stock hits 52-week low at $13.48 - MSN
Arcus Biosciences stock hits 52-week low at $13.48 By Investing.com - Investing.com Canada
Cantor Fitzgerald Weighs in on RCUS FY2025 Earnings - MarketBeat
Financial Survey: Barinthus Biotherapeutics (NASDAQ:BRNS) & Arcus Biosciences (NYSE:RCUS) - Defense World
Arcus Biosciences Appoints Richard Markus, M.D., Ph.D. as Chief Medical Officer - BioSpace
Arcus Biosciences appoints new Chief Medical Officer By Investing.com - Investing.com South Africa
Arcus Biosciences appoints new Chief Medical Officer - Investing.com
Arcus Biosciences Announces New Chief Medical Officer - TipRanks
Arcus Biosciences, Inc. (NYSE:RCUS) Given Average Rating of “Buy” by Analysts - Defense World
Arcus Biosciences, Inc. (NYSE:RCUS) Given Average Rating of "Buy" by Analysts - MarketBeat
Wells Fargo Initiates Coverage of Arcus Biosciences (RCUS) with Overweight Recommendation - MSN
Undercovered Dozen: Lincoln National, Whitecap Resources, NMI Holdings, Healwell AI + - Seeking Alpha
How the (RCUS) price action is used to our Advantage - Stock Traders Daily
Arcus Biosciences: Many Important Oncology Catalysts Coming Up In 2025 - Seeking Alpha
Arcus Biosciences stock hits 52-week low at $13.51 By Investing.com - Investing.com Canada
Arcus Biosciences (NYSE:RCUS) Sets New 52-Week LowTime to Sell? - MarketBeat
Arcus: Excellent Pipeline And Collaborations, Cash Runway (NYSE:RCUS) - Seeking Alpha
Arcus Biosciences (NYSE:RCUS investor three-year losses grow to 60% as the stock sheds US$79m this past week - Simply Wall St
Robert C. Goeltz II Sells 3,594 Shares of Arcus Biosciences, Inc. (NYSE:RCUS) Stock - MarketBeat
Principal Financial Group Inc. Sells 18,777 Shares of Arcus Biosciences, Inc. (NYSE:RCUS) - Defense World
Geode Capital Management LLC Has $18.69 Million Stock Holdings in Arcus Biosciences, Inc. (NYSE:RCUS) - Defense World
Barclays PLC Grows Position in Arcus Biosciences, Inc. (NYSE:RCUS) - Defense World
Arcus Biosciences, Inc. (NYSE:RCUS) Shares Purchased by Barclays PLC - MarketBeat
(RCUS) Trading Report - Stock Traders Daily
Arcus Biosciences, Inc. (NYSE:RCUS) Given Consensus Rating of "Buy" by Analysts - MarketBeat
Arcus Biosciences, Inc. (NYSE:RCUS) Given Consensus Rating of “Buy” by Brokerages - Defense World
Arcus Biosciences Grants Stock Options, RSUs to New Employees Under Inducement Plan - StockTitan
0.82%
0.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):